Skip to main content

Table 3 Clinical characteristics between PARP1 low and high expression groups

From: Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Characteristic Total (n = 72) PARP1 expression PARP1 expression P-value
Low High
Age (year)     0.238
 < 55 36 (50.0) 21 (29.2) 15 (20.8)  
 ≥ 55 36 (50.0) 15 (20.8) 21 (29.2)  
FIGO stage (2014)     0.710
 I and II 8 (11.1) 3 (4.2) 5 (6.9)  
 III and IV 64 (88.9) 33 (45.8) 31 (43.1)  
Diameter (cm)     0.813
 < 8 40 (55.6) 19 (26.4) 21 (29.2)  
 ≥ 8 32 (44.4) 17 (23.6) 15 (20.8)  
Ascitic fluid     0.312
 Yes 23 (31.9) 9 (12.5) 14 (19.4)  
 NO 49 (68.1) 27 (37.5) 22 (30.6)  
CA125 (U/ml)     0.115
 < 35 4 (5.6) 0 (0.0) 4 (5.6)  
 ≥ 35 68 (94.4) 36 (50.0) 32 (44.4)  
PD-L1 expression     0.341
 Low 41 (56.9) 23 (31.9) 18 (25.0)  
 High 31 (43.1) 13 (18.1) 18 (25.0)  
CD8 expression (cancer tissue)    0.240
 Low 38 (52.8) 17 (23.6) 21 (29.2)  
 High 34 (47.2) 19 (26.4) 15 (20.8)  
  1. Values are n (%)
  2. FIGO, International Federation of Gynecology and Obstetrics; CA125, carbohydrate antigen; PARP1, poly-ADP-ribose polymerase 1; PD-L1, programmed death ligand 1